A Randomised, Double-blind, Placebo-controlled 4-period Cross-over Study to Assess the Efficacy and Safety of Repeat Dose Intranasal GSK1004723 (1000microg), Oral GSK835726 (10mg) and Cetirizine (10mg) in the Environmental Challenge Chamber in Subjects With Seasonal Allergic Rhinitis.
Latest Information Update: 06 Sep 2023
At a glance
- Drugs GSK 1004723 (Primary) ; GSK 835726 (Primary) ; Cetirizine
- Indications Seasonal allergic rhinitis
- Focus Therapeutic Use
- Sponsors GSK
- 11 Sep 2009 New trial record